全文获取类型
收费全文 | 7703篇 |
免费 | 642篇 |
国内免费 | 75篇 |
专业分类
耳鼻咽喉 | 69篇 |
儿科学 | 356篇 |
妇产科学 | 194篇 |
基础医学 | 984篇 |
口腔科学 | 147篇 |
临床医学 | 738篇 |
内科学 | 1849篇 |
皮肤病学 | 72篇 |
神经病学 | 908篇 |
特种医学 | 277篇 |
外科学 | 815篇 |
综合类 | 140篇 |
一般理论 | 2篇 |
预防医学 | 873篇 |
眼科学 | 128篇 |
药学 | 306篇 |
中国医学 | 2篇 |
肿瘤学 | 560篇 |
出版年
2021年 | 73篇 |
2019年 | 67篇 |
2018年 | 102篇 |
2017年 | 82篇 |
2016年 | 78篇 |
2015年 | 98篇 |
2014年 | 165篇 |
2013年 | 226篇 |
2012年 | 305篇 |
2011年 | 296篇 |
2010年 | 208篇 |
2009年 | 208篇 |
2008年 | 333篇 |
2007年 | 348篇 |
2006年 | 303篇 |
2005年 | 295篇 |
2004年 | 272篇 |
2003年 | 327篇 |
2002年 | 283篇 |
2001年 | 265篇 |
2000年 | 271篇 |
1999年 | 248篇 |
1998年 | 112篇 |
1997年 | 118篇 |
1996年 | 88篇 |
1995年 | 87篇 |
1994年 | 87篇 |
1993年 | 80篇 |
1992年 | 220篇 |
1991年 | 225篇 |
1990年 | 198篇 |
1989年 | 181篇 |
1988年 | 174篇 |
1987年 | 173篇 |
1986年 | 135篇 |
1985年 | 169篇 |
1984年 | 115篇 |
1983年 | 86篇 |
1982年 | 73篇 |
1981年 | 75篇 |
1979年 | 120篇 |
1978年 | 95篇 |
1977年 | 59篇 |
1976年 | 70篇 |
1975年 | 64篇 |
1974年 | 72篇 |
1973年 | 58篇 |
1972年 | 71篇 |
1970年 | 49篇 |
1966年 | 53篇 |
排序方式: 共有8420条查询结果,搜索用时 31 毫秒
991.
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence,migration, and antitumor effect of transferred T cells 总被引:5,自引:0,他引:5
下载免费PDF全文
![点击此处可从《Proceedings of the National Academy of Sciences of the United States of America》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Yee C Thompson JA Byrd D Riddell SR Roche P Celis E Greenberg PD 《Proceedings of the National Academy of Sciences of the United States of America》2002,99(25):16168-16173
Adoptive T cell therapy, involving the ex vivo selection and expansion of antigen-specific T cell clones, provides a means of augmenting antigen-specific immunity without the in vivo constraints that can accompany vaccine-based strategies. A phase I study was performed to evaluate the safety, in vivo persistence, and efficacy of adoptively transferred CD8+ T cell clones targeting the tumor-associated antigens, MART1MelanA and gp100 for the treatment of patients with metastatic melanoma. Four infusions of autologous T cell clones were administered, the first without IL-2 and subsequent infusions with low-dose IL-2 (at 0.25, 0.50, and 1.0 x 10(6) unitsm(2) twice daily for the second, third, and fourth infusions, respectively). Forty-three infusions of MART1MelanA-specific or gp100-specific CD8+ T cell clones were administered to 10 patients. No serious toxicity was observed. We demonstrate that the adoptively transferred T cell clones persist in vivo in response to low-dose IL-2, preferentially localize to tumor sites and mediate an antigen-specific immune response characterized by the elimination of antigen-positive tumor cells, regression of individual metastases, and minor, mixed or stable responses in 8 of 10 patients with refractory, metastatic disease for up to 21 mo. 相似文献
992.
Ross AA; Cooper BW; Lazarus HM; Mackay W; Moss TJ; Ciobanu N; Tallman MS; Kennedy MJ; Davidson NE; Sweet D 《Blood》1993,82(9):2605-2610
Although peripheral blood stem cell collections (PBSC) are thought to have less tumor involvement than bone marrow (BM), the incidence of circulating tumor cells in patients with breast cancer has not been widely investigated. We prospectively investigated the incidence and viability of tumor cell involvement in PBSC and BM collections from breast cancer patients undergoing high-dose chemotherapy/hematopoietic stem cell transplantation. Paired samples of PBSC and BM from 48 patients were analyzed using an immunocytochemical technique that detects one epithelial-derived tumor cell per 5 x 10(5) mononuclear cells. Immunostained tumor cells were detected in 9.8% (13/133) PBSC specimens from 9/48 (18.7%) patients and in 62.3% (38/61) BM specimens from 32/48 (66.7%) patients, a significantly higher rate than in PBSC (P < .005). The geometric mean concentration of tumor cells in contaminated PBSC specimens was 0.8/10(5) mononuclear cells (range 0.33 to 2.0/10(5)) compared with 22.9/10(5) mononuclear cells in BM (range 1 to 3,000/10(5), P < .0001). In culture experiments, clonogenic tumor colonies grew in 21/26 immunocytochemically positive specimens. No tumor colony growth was detected in 30/32 immunocytochemically negative specimens. Immunocytochemical detection of tumor involvement in BM and PBSC correlated significantly with in vitro clonogenic growth (P < .0001). We conclude that PBSC contain fewer tumor cells than paired BM specimens from patients with advanced breast cancer and that these tumor cells appear to be capable of clonogenic growth in vitro. 相似文献
993.
OBJECTIVE: To determine the frequency and severity of kidney abnormalities in patients with diffuse scleroderma. METHODS: All patients with diffuse scleroderma seen at the University of Pittsburgh between 1972 and 1993 were included in the study. Kidney function tests were routinely obtained as part of the Pittsburgh Scleroderma Outcome Study. Additional kidney tests were obtained as part of the 1992 biannual outcome assessment. Patients who had kidney abnormalities including a serum creatinine > 1.2 mg/dl or proteinuria prior to 1993 were identified. The clinical setting and longterm outcome of kidney disease were evaluated. RESULTS: Renal crisis occurred in 129/675 (19.5%) patients. Kidney function abnormalities or proteinuria were present in 173 (26%); 48% had no abnormalities. Most patients had other explanations for the abnormality. Only 12 (2%) of the 675 patients with diffuse scleroderma had no explanation for the elevated creatinine level. Most patients with proteinuria had toxicity from D-penicillamine. No explanations for proteinuria were found in 16 (2%) of this cohort. Thus, a total of only 28 (4%) of these 675 patients had an unknown cause for their kidney dysfunction or proteinuria. None of these patients, who were followed for a mean of 10 years after onset of scleroderma, have developed chronic renal insufficiency that progressed to dialysis. CONCLUSION: Patients with diffuse scleroderma without renal crisis rarely have significant increases in serum creatinine or proteinuria that cannot be explained by other etiologies. These patients with scleroderma should be carefully evaluated for non-scleroderma causes of kidney disease. 相似文献
994.
Metabolic, psychological, and health correlates of dietary restraint in healthy postmenopausal women
Bathalon GP Hays NP Meydani SN Dawson-Hughes B Schaefer EJ Lipman R Nelson M Greenberg AS Roberts SB 《The journals of gerontology. Series A, Biological sciences and medical sciences》2001,56(4):M206-M211
BACKGROUND: Dietary restraint, a term used to describe the intentional control of food intake to prevent weight gain or promote weight loss, is commonly practiced by older adults, but little is known about its effects on physiology and metabolism. METHODS: We therefore compared a wide range of parameters between groups of healthy non-obese postmenopausal women classified psychometrically as unrestrained eaters (body mass index [BMI] 23.8 +/- 0.6 [SEM] kg/m(2), n = 28) or restrained eaters (BMI 24.5 +/- 0.5, n = 39). Measurements were made of reported micronutrient intakes, cardiopulmonary function, hematology, body temperature, skin thickness, bone mass, and immune function; in addition, self-perceived health, mood, and some dimensions of eating behavior were assessed by questionnaire. RESULTS: Macronutrient and micronutrient intakes were not significantly different between restrained and unrestrained eaters reporting energy intake to within 30% of predicted total energy expenditure. Restrained eaters had significantly lower hemoglobin (12.9 +/- 0.1 [SEM] vs 13.2 +/- 0.1 g/dl; p <.05), but values were within the normal range in both groups. In addition, restrained eaters scored significantly higher on the Eating Attitudes Test (p <.01) and drive-for-thinness (p <.001) and maturity fears (p <.05) subscores of the Eating Disorders Inventory, but values were again within the normal range. No other parameter differed significantly between groups. CONCLUSIONS: In this normal-weight population, restrained eating was not associated with detrimental effects in a wide range of physiological, metabolic, and health characteristics. Further work is needed to determine the relevance of these results to the general population. 相似文献
995.
996.
997.
Delbert G. Robinson Juan A. Gallego Majnu John Georgios Petrides Youssef Hassoun Jian-Ping Zhang Leonardo Lopez Raphael J. Braga Serge M. Sevy Jean Addington Charles H. Kellner Mauricio Tohen Melissa Naraine Natasha Bennett Jessica Greenberg Todd Lencz Christoph U. Correll John M. Kane Anil K. Malhotra 《Schizophrenia bulletin》2015,41(6):1227-1236
Research findings are particularly important for medication choice for first-episode patients as individual prior medication response to guide treatment decisions is unavailable. We describe the first large-scale double-masked randomized comparison with first-episode patients of aripiprazole and risperidone, 2 commonly used first-episode treatment agents. One hundred ninety-eight participants aged 15–40 years with schizophrenia, schizophreniform disorder, schizoaffective disorder or psychotic disorder Not Otherwise Specified, and who had been treated in their lifetime with antipsychotics for 2 weeks or less were randomly assigned to double-masked aripiprazole (5–30mg/d) or risperidone (1–6mg/d) and followed for 12 weeks. Positive symptom response rates did not differ (62.8% vs 56.8%) nor did time to response. Aripiprazole-treated participants had better negative symptom outcomes but experienced more akathisia. Body mass index change did not differ between treatments but advantages were found for aripiprazole treatment for total and low-density lipoprotein cholesterol, fasting glucose, and prolactin levels. Post hoc analyses suggested advantages for aripiprazole on depressed mood. Overall, if the potential for akathisia is a concern, low-dose risperidone as used in this trial maybe a preferred choice over aripiprazole. Otherwise, aripiprazole would be the preferred choice over risperidone in most situations based upon metabolic outcome advantages and some symptom advantages within the context of similar positive symptom response between medications.Key words: clinical trial, treatment response, negative symptoms, akathisia, metabolic side effects 相似文献
998.
IgG4‐related disease (IgG4‐RD) has emerged as a new entity in the last decade. It comprises numerous conditions previously thought to be unrelated. Macroscopically, these diseases cause diffuse organ swelling and formation of pseudotumorous masses. Histopathologically, they are characterized by a lymphoplasmacytic infiltrate with increased IgG4+ plasma cells and storiform fibrosis. Despite rapid progress within the last years, our knowledge on these conditions is still fragmented. To date, more than forty organs have been reported to be included in IgG4‐RD, and salivary gland involvement is amongst the most common organs affected [IgG4‐related sialadenitis (IgG4‐RS)]. Interestingly, IgG4‐RS shares commonalities with Sjögren's syndrome (SS), like glandular enlargement, sicca symptoms, arthralgias, hypergammaglobulinemia, hypocomplementemia, and circulating antinuclear antibodies. Nonetheless, they differ in that the incidence of anti‐Ro and anti‐La reactivity is not frequently found in patients with IgG4‐RS, their salivary glands are infiltrated by a large number of IgG4+ plasma cells and IgG4‐RS symptoms respond promptly to steroids. The aim of this review was to describe the clinical, serological, histopathological and pathophysiological aspects of IgG4‐RS in the context of IgG4‐RD and highlight the differences between IgG4‐RS and SS. 相似文献
999.
J. Greenberg J. R. Curtis M. Liu M. E. Farkouh P. Tsao J. M. Kremer C. J. Etzel 《Arthritis \u0026amp; Rheumatology》2015,67(8):1995-2003
1000.